Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice.

NCT06864026 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06864026
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06864026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice.
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Active, not recruiting
Start date
March 6, 2025
Completion date
August 31, 2027
Enrollment
200 (estimated)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

overweight or obesity, psoriatic arthritis